683 related articles for article (PubMed ID: 20410233)
21. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
22. Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues.
Wahid ST; Marbach P; Stolz B; Miller M; James RA; Ball SG
Eur J Endocrinol; 2002 Mar; 146(3):295-302. PubMed ID: 11888834
[TBL] [Abstract][Full Text] [Related]
23. Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly.
Chang JS; Tseng HM; Chang TC
J Formos Med Assoc; 2016 Jun; 115(6):475-80. PubMed ID: 27117887
[TBL] [Abstract][Full Text] [Related]
24. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
Boscaro M; Ludlam WH; Atkinson B; Glusman JE; Petersenn S; Reincke M; Snyder P; Tabarin A; Biller BM; Findling J; Melmed S; Darby CH; Hu K; Wang Y; Freda PU; Grossman AB; Frohman LA; Bertherat J
J Clin Endocrinol Metab; 2009 Jan; 94(1):115-22. PubMed ID: 18957506
[TBL] [Abstract][Full Text] [Related]
25. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients.
Colao A; Pivonello R; Auriemma RS; Briganti F; Galdiero M; Tortora F; Caranci F; Cirillo S; Lombardi G
J Clin Endocrinol Metab; 2006 Jun; 91(6):2112-8. PubMed ID: 16537687
[TBL] [Abstract][Full Text] [Related]
26. Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease.
Ben-Shlomo A; Melmed S
IDrugs; 2007 Dec; 10(12):885-95. PubMed ID: 18041687
[TBL] [Abstract][Full Text] [Related]
27. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
[TBL] [Abstract][Full Text] [Related]
28. Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study.
Colao A; Bronstein MD; Brue T; De Marinis L; Fleseriu M; Guitelman M; Raverot G; Shimon I; Fleck J; Gupta P; Pedroncelli AM; Gadelha MR
Eur J Endocrinol; 2020 Jun; 182(6):583. PubMed ID: 32217809
[TBL] [Abstract][Full Text] [Related]
29. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly.
Attanasio R; Baldelli R; Pivonello R; Grottoli S; Bocca L; Gasco V; Giusti M; Tamburrano G; Colao A; Cozzi R
J Clin Endocrinol Metab; 2003 Nov; 88(11):5258-65. PubMed ID: 14602759
[TBL] [Abstract][Full Text] [Related]
30. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study.
Colao A; Auriemma RS; Galdiero M; Lombardi G; Pivonello R
J Clin Endocrinol Metab; 2009 Oct; 94(10):3746-56. PubMed ID: 19622615
[TBL] [Abstract][Full Text] [Related]
31. A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers.
Golor G; Hu K; Ruffin M; Buchelt A; Bouillaud E; Wang Y; Maldonado M
Drug Des Devel Ther; 2012; 6():71-9. PubMed ID: 22573933
[TBL] [Abstract][Full Text] [Related]
32. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache.
Marina D; Burman P; Klose M; Casar-Borota O; Luque RM; Castaño JP; Feldt-Rasmussen U
Growth Horm IGF Res; 2015 Oct; 25(5):262-7. PubMed ID: 26188991
[TBL] [Abstract][Full Text] [Related]
33. Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control.
Shimon I; Saeger W; Wildemberg LE; Gadelha MR
Hormones (Athens); 2017 Jan; 16(1):84-91. PubMed ID: 28500831
[TBL] [Abstract][Full Text] [Related]
34. Pasireotide (SOM230): development, mechanism of action and potential applications.
Schmid HA
Mol Cell Endocrinol; 2008 May; 286(1-2):69-74. PubMed ID: 17977644
[TBL] [Abstract][Full Text] [Related]
35. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.
Feelders RA; Hofland LJ; van Aken MO; Neggers SJ; Lamberts SW; de Herder WW; van der Lely AJ
Drugs; 2009 Nov; 69(16):2207-26. PubMed ID: 19852525
[TBL] [Abstract][Full Text] [Related]
36. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
[TBL] [Abstract][Full Text] [Related]
37. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
38. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient.
Resmini E; Dadati P; Ravetti JL; Zona G; Spaziante R; Saveanu A; Jaquet P; Culler MD; Bianchi F; Rebora A; Minuto F; Ferone D
J Clin Endocrinol Metab; 2007 May; 92(5):1592-9. PubMed ID: 17311860
[TBL] [Abstract][Full Text] [Related]
39. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly.
Andries M; Glintborg D; Kvistborg A; Hagen C; Andersen M
Clin Endocrinol (Oxf); 2008 Mar; 68(3):473-80. PubMed ID: 17941902
[TBL] [Abstract][Full Text] [Related]
40. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.
Kvols LK; Oberg KE; O'Dorisio TM; Mohideen P; de Herder WW; Arnold R; Hu K; Zhang Y; Hughes G; Anthony L; Wiedenmann B
Endocr Relat Cancer; 2012 Oct; 19(5):657-66. PubMed ID: 22807497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]